Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, respectively. Given their effectiveness as single agents in mIDH1/2 relapsed or refractory acute myeloid leukemia (AML), this phase 1 study evaluated the safety and...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Blood
Κύριοι συγγραφείς: Stein, Eytan M., DiNardo, Courtney D., Fathi, Amir T., Mims, Alice S., Pratz, Keith W., Savona, Michael R., Stein, Anthony S., Stone, Richard M., Winer, Eric S., Seet, Christopher S., Döhner, Hartmut, Pollyea, Daniel A., McCloskey, James K., Odenike, Olatoyosi, Löwenberg, Bob, Ossenkoppele, Gert J., Patel, Prapti A., Roshal, Mikhail, Frattini, Mark G., Lersch, Frederik, Franovic, Aleksandra, Nabhan, Salah, Fan, Bin, Choe, Sung, Wang, Hongfang, Wu, Bin, Hua, Lei, Almon, Caroline, Cooper, Michael, Kantarjian, Hagop M., Tallman, Martin S.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2021
Θέματα:
Myeloid Neoplasia
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020270/
https://ncbi.nlm.nih.gov/pubmed/33024987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007233
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια